0001493152-21-015911.txt : 20210701 0001493152-21-015911.hdr.sgml : 20210701 20210701215631 ACCESSION NUMBER: 0001493152-21-015911 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210330 FILED AS OF DATE: 20210701 DATE AS OF CHANGE: 20210701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boehm Marcus CENTRAL INDEX KEY: 0001850698 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 211067879 MAIL ADDRESS: STREET 1: C/O VYANT BIO, INC. STREET 2: 201 ROUTE 17 NORTH, 2ND FLOOR CITY: RUTHERFORD STATE: NJ ZIP: 07070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 4/A 1 ownership.xml X0306 4/A 2021-03-30 2021-04-01 0 0001349929 Vyant Bio, Inc. VYNT 0001850698 Boehm Marcus C/O VYANT BIO, INC. 2370 STATE ROUTE 70, SUITE 310 CHERRY HILL, NJ 08002 1 0 0 0 Common Stock, $0.0001 par value 2021-03-30 4 J 0 93786 A 93786 D Common Stock, $0.0001 par value 2021-05-05 5 G 0 E 78263 0 D 15253 D Common Stock, $0.0001 par value 2021-05-05 5 G 0 E 78263 0 A 78263 I By Trust Common Stock, $0.0001 par value 2021-05-10 5 G 0 E 15523 0 D 0 D Common Stock, $0.0001 par value 2021-05-10 5 G 0 E 15523 0 A 93786 I By Trust Common Stock, $0.0001 par value 2021-05-28 4 P 0 5000 3.68 A 98786 I By Trust Common Stock, $0.0001 par value 2021-06-30 4 P 0 5000 3.7649 A 103786 I By Trust Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person under the Boehm Family Trust, Marcus & Kimberley Boehm Trustees on May 24, 2021. Shares were previously reported as being directly held by reporting person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.8099 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. This amended Form 4 is being filed to correct (i) the number of shares issued pursuant to the merger on March 30, 2021, (ii) reporting person's indirect purchase of shares (via a trust) on May 28, 2021 and (iii) the disclosure of shares previously owned directly that were transferred to a trust reported on the Form 4 filed July 1, 2021. /s/ Andrew LaFrence, attorney-in-fact 2021-07-01